A randomized parallel-group controlled study for personalized postoperative pain management based on prediction of fentanyl requirements by genetic polymorphisms in patients undergoing orthognathic surgery

A randomized parallel-group controlled study for personalized postoperative pain management based on prediction of fentanyl requirements by genetic polymorphisms in patients undergoing orthognathic surgery - A controlled study on efficacy of personalized postoperative pain management by determining genetic polymorphisms in patients undergoing orthognathic surgery

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006805

Enrollment

300

Registered

2012-01-01

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Personalized dose : transitional opioid (fentanyl = dose predicted by polymorphisms) and IV-PCA dose (fentanyl = dose predicted by polymorphisms / 1injection) for postoperative 24 h Normal dose : tran

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who undergo orthognathic surgery and agree to participate in the study with written informed consent

Exclusion criteria

Exclusion criteria: Patients less than 15 years and more than 60 years or those with severe complications

Design outcomes

Secondary

Measure	Time frame
Intravenous-Patient-controlled analgesia (IV-PCA) requirements for postoperative 24 h, visual analog scale, side effects (heart rate, blood pressure, SpO2, breathing, sedation score)	—

Primary

Measure	Time frame
Predictability of Intravenous-Patient-controlled analgesia (IV-PCA) requirements for postoperative 24 h, patient's satisfaction, and/or composite endpoint including side effects	—

Countries

Japan

Contacts

Public ContactKazutaka Ikeda

Tokyo Metropolitan Institute of Medical Science Addictive Substance Project

ikeda-kz@igakuken.or.jp03-6834-2379(EXT-3825)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026